gms | German Medical Science

22nd Annual Meeting of the German Retina Society

German Retina Society

26.06. - 27.06.2009, Berlin

VEGF antibodies in the retina of monkeys and humans

Meeting Abstract

Search Medline for

  • Peter Heiduschka - University Eye Clinic of Tuebingen
  • U. Schraermeyer - University Eye Clinic of Tuebingen

German Retina Society. 22nd Annual Meeting of the German Retina Society. Berlin, 26.-27.06.2009. Düsseldorf: German Medical Science GMS Publishing House; 2009. DocRG2009-04

doi: 10.3205/09rg04, urn:nbn:de:0183-09rg044

This is the translated version of the article.
The original version can be found at: http://www.egms.de/de/meetings/rg2009/09rg04.shtml

Published: June 29, 2009

© 2009 Heiduschka et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en). You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.


Outline

Text

Since a couple of years, the antibody bevacizumab (Avastin™) and the antibody fragment ranibizumab (Lucentis™) have been applied successfully in patients suffering from \'22wet\'22 AMD and other neurovascular eye diseases. The antibody fragment ranibizumab was developed under the assumption that complete antibodies would not be able to penetrate the retina due to their size in order to reach the site of their action, the subretinal space. However, facing the clinical success of the off-label use of Avastin™, this assumption was challenged. Recently, we could show by immunohistochemical staining that bevacizumab actually penetrates the retina after an intravitreal injection of Avastin™ in monkeys. Bevacizumab is taken up by several cell in the retina, in particular by photoreceptors, where it can be detected in the outer segments. Intravitreally injected bevacizumab could also be detected already one day later in the systemic blood circulation, as well as in choroidal blood vessels, starting from day one after injection, and increasingly later on. As bevacizumab penetrated the retina, no more VEGF could be detected in the penetrated area. In the meantime, we are also able to study ex vivo the retinal penetration of the antibody fragment ranibizumab by establishing an immunohistochemical detection method for ranibizumab in our lab. This way, we found that also ranibizumab is taken up by several neuronal cells in the retina.